SUPN
Supernus Pharmaceuticals, Inc.Company with tickers: SUPN
CIK
1356576
CUSIP
868459108
Shares Outstanding
58,039,721
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $207,705,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $39,438,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Operating Income | $-8,332,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | $-2,293,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | $-0.04 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $-0.04 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |